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PN-Terminal Pro–B-Type Natriuretic
Peptide-Guided Treatment for Chronic Heart Failure
Results From the BATTLESCARRED (NT-proBNP–Assisted
Treatment To Lessen Serial Cardiac Readmissions and Death) Trial
John G. Lainchbury, MD, Richard W. Troughton, MD, PHD, Kim M. Strangman, RN,
Christopher M. Frampton, PHD, Anna Pilbrow, PHD, Timothy G. Yandle, PHD,
Amjad K. Hamid, MBCHB, M. Gary Nicholls, MD, A. Mark Richards, MD, PHD
Christchurch, New Zealand
Objectives The purpose of this study was to compare the effects of N-terminal pro–B-type natriuretic peptide (NT-proBNP)-
guided therapy with those of intensive clinical management and with usual care (UC) on clinical outcomes in
chronic symptomatic heart failure.
Background Initial trial results suggest titration of therapy guided by serial plasma B-type natriuretic peptide levels improves
outcomes in patients with chronic heart failure, but the concept has not received widespread acceptance. Ac-
cordingly, we conducted a longer-term study comparing the effects of NT-proBNP–guided therapy with those of
intensive clinical management and with UC of patients with heart failure.
Methods Three hundred sixty-four patients admitted to a single hospital with heart failure were randomly allocated 1:1:1
(stratified by age) to therapy guided by NT-proBNP levels or by intensive clinical management, or according to
UC. Treatment strategies were applied for 2 years with follow-up to 3 years.
Results One-year mortality was less in both the hormone- (9.1%) and clinically-guided (9.1%) groups compared with UC
(18.9%; p  0.03). Three-year mortality was selectively reduced in patients 75 years of age receiving hormone-
guided treatment (15.5%) compared with their peers receiving either clinically managed treatment (30.9%;
p  0.048) or UC (31.3%; p  0.021).
Conclusions Intensive management of chronic heart failure improves 1-year mortality compared with UC. Compared with clin-
ically guided treatment and UC, hormone-guided treatment selectively improves longer-term mortality in patients
75 years of age. (NT-proBNP–Assisted Treatment To Lessen Serial Cardiac Readmissions and Death
[BATTLESCARRED]; Australian New Zealand Clinical Trials Registry 12605000735651) (J Am Coll Cardiol
2010;55:53–60) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.02.095T
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croven treatments in chronic heart failure (CHF) include
ngiotensin-converting enzyme inhibitors (ACEIs) (1), an-
iotensin receptor blockers (ARBs) (2), beta-adrenergic
lockers (BBs) (3), and spironolactone (4). Whether drug
oses should be the same for all or individually “tailored” is
nclear. Individualized treatment may be optimal for pa-
ients with few limiting factors but impossible for others,
ncluding elderly, hypotensive, or renally impaired patients.
rom the Department of Medicine, Christchurch Cardioendocrine Research Group,
niversity of Otago, Christchurch, New Zealand. This trial was supported by grants
rom the Health Research Council of New Zealand and the National Heart
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iagnostics. Dr. Richards is a recipient of honoraria and research grants from Roche
iagnostics.e
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009, accepted February 24, 2009.esting of tailored therapy has hitherto been limited by the
bsence of a reliable, readily accessible index of cardiac
ysfunction. Plasma B-type natriuretic peptide (BNP) mea-
urements reflect left ventricular function (5,6) and progno-
is in CHF (7). Drug- and device-induced improvements in
ardiac status are paralleled by falls in peptide levels (8–10).
See page 61
herefore, serial measurements of plasma BNP or
-terminal pro–B-type natriuretic peptide (NT-proBNP)
ight prove useful in optimizing pharmacotherapy for CHF.
wo trials have reported that hormone-guided treatment of
HF improves outcomes compared with conventional,
linically-guided (CG) therapy (11,12). These trials have
xcluded patients with CHF and preserved left ventricular
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not included a parallel group of
patients cared for in the commu-
nity by primary care physicians,
and have been relatively small
and brief. One such trial was
carried out before BBs were in
widespread use for the treatment
of CHF (11).
Uncertainty surrounding this is-
sue is encapsulated by the 2007
guidelines for the clinical utiliza-
tion of cardiac biomarker testing in
heart failure, which state: “. . .the
concept of natriuretic peptide-
guided management of heart fail-
ure is still debated, and there is no
general consensus in expert opinion
regarding this issue” (13). We de-
signed the BATTLESCARRED
(NT-proBNP–Assisted Treatment
To Lessen Serial Cardiac Readmis-
ions and Death) trial, a randomized, controlled trial that com-
ared usual care (UC), intensive standardized clinical manage-
ent, and NT-proBNP–guided therapy for CHF.
ethods
rial design and methods have been published (14) and
egistered with the Australian Clinical Trials Registry.
hree hypotheses were addressed: First, that titration of
edication aimed at reducing plasma levels of NT-proBNP
o 150 pmol/l (1,300 pg/ml) or based on intensive
tandardized clinical assessment would result in outcomes
uperior to those of UC. Second, that drug treatment
itrated according to plasma NT-proBNP levels would
mprove clinical outcomes compared with treatment guided
y intensive standardized clinical assessment. Third, that
he clinical efficacy of NT-proBNP–guided therapy would
e influenced by age.
tudy population. Inclusion required age 18 years and
ymptomatic CHF, defined by Framingham criteria (15)
nd satisfying European Society of Cardiology diagnostic
uidelines (16), precipitating admission, and ability to give
nformed consent. Immediate pre-randomization plasma
T-proBNP levels had to exceed 50 pmol/l (400 pg/ml).
xclusion criteria included active myocarditis/pericarditis,
ife expectancy due to noncardiovascular disease of 24
onths, severe hepatic or pulmonary disease (forced expi-
atory volume in 1 s of 1 l), severe renal impairment
plasma creatinine 250 mol/l), severe valvular disease, or
andidacy for cardiac transplantation. Recruitment deliber-
tely included elderly patients and patients with a preserved
VEF.
rocedures. During index admissions, treatment was ac-
Abbreviations
and Acronyms
ACEI  angiotensin-
converting enzyme inhibitor
ARB  angiotensin
receptor blocker
BB  beta-adrenergic
blocker
BNP  B-type natriuretic
peptide
CG  clinically guided
CHF  chronic heart failure
LVEF  left ventricular
ejection fraction
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
NYHA  New York Heart
Association
UC  usual careording to the usual practice of the admitting physician.ualifying patients attended a research outpatient clinic
ithin 2 weeks of discharge from hospital and were ran-
omly assigned, in a double-blind fashion, to 1 of 3
reatments in a 1:1:1 ratio, stratified by age (75 or 75
ears) in permuted blocks of 30. The UC group had no
urther contact with the research team beyond 3-monthly
ocumentation of medications, readmissions, and death.
heir management was undertaken in primary care with or
ithout additional attendance of hospital cardiology or
pecialist heart failure clinics as requested by their primary
are physician. Patients randomly allocated to the hormone-
uided (NT-proBNP) and CG groups were seen at
-monthly intervals in a dedicated research clinic. At each
isit, clinical assessment was undertaken by staff blinded to
he patient’s assigned trial group to ascertain a heart failure
core, derived by assigning a value to variables included in
he Framingham method for the diagnosis of heart failure,
ith major criteria scoring 1 point and minor criteria, 0.5
oints (Table 1) (11,14,15). Clinical end points were doc-
mented and blood drawn for NT-proBNP (17) and
iochemistry, including plasma creatinine for estimation of
he glomerular filtration rate (18). New York Heart Asso-
iation (NYHA) functional class (3-monthly), 6-min walk
ests (baseline and 6 and 12 months), Minnesota Living
ith Heart Failure quality of life scores (baseline and 6 and
2 months), blood pressure, and heart rate (all visits) were
ocumented. Both groups received instructions on moni-
oring weight, dietary sodium restriction, rest after diuretic
dministration, exercise, avoidance of licorice, nonsteroidal
nti-inflammatory drugs, and alcohol, and the need for
nfluenza vaccination.
For the CG group, we aimed to establish trial-based
rug doses. This included the equivalent of enalapril 10 mg
wice daily adjusted for renal function. Beta-blockers were
ntroduced with standard titration at 2-weekly intervals toward
oses of carvedilol 25 mg twice daily or a sustained-release
reparation of metoprolol to 190 mg daily. Heart failure scores
2.0 triggered escalation of drug therapy according to a pre-set
lgorithm.
For the NT-proBNP group, adjustments in medications
nd additional follow-up visits were triggered by an NT-
eart Failure ScoreTable 1 Heart Failure Score
Symptom/Sign Value Score
Orthopnea 0.5
Paroxysmal nocturnal dyspnea 1.0
Reduction in exercise tolerance 0.5
Resting sinus tachycardia (1001) 0.5
Jugular venous pressure 4 cm 0.5
Hepatojugular reflux positive 1.0
Third heart sound present 1.0
Basal crackles 1.0
Hepatomegaly 0.5
Peripheral edema 0.5Total score
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December 29, 2009/January 5, 2010:53–60 Hormone-Guided Treatment of Heart FailureroBNP level150 pmol/l and/or a heart failure score2.0
ccording to instructions by 1 investigator (J.G.L.) who did
ot undertake the clinical assessments. When results fell
elow both thresholds, treatment was not altered. Serial
ssessments were conducted as for the CG group.
Trial treatment protocols were applied for 2 years from
andomization after which patients were returned to stan-
ard management. Outcomes were documented at 1 and 2
ears and, for the coprimary end points, also at 3 years.
utcomes. Primary outcomes included all-cause mortality
nd the composite of death plus hospitalization for heart
ailure. Secondary outcomes were death plus hospital ad-
ission for any cardiovascular event plus episodes of out-
atient decompensated heart failure requiring increased
edications; any episode of heart failure decompensation;
otal admissions to hospital; and changes in NT-proBNP
evels, NYHA status, 6-min walk distance, and Minnesota
iving With Heart Failure quality of life scores.
tatistical analysis. Data are presented as mean  SD
when normally distributed) or median and interquartile
ange. The appropriateness of parametric analyses was
onfirmed by visual inspection of the normality and vari-
bility of residual plots. When these assumptions were not
et, data were log transformed before analyses or nonpara-
etric tests were employed. Baseline variables were com-
ared between treatment groups using t tests, Mann-
hitney U statistic, chi-square test, and Fisher exact test as
ppropriate. Variables undergoing serial measurements were
nalyzed by analysis of variance with repeated measures
ncluding time, group, and time by group interaction terms.
here significant main or interaction effects were detected,
hese were further explored as within subject and between
ubject effects using post-hoc paired and independent
tests.
Clinical outcomes were tested on an intention to treat
asis using the Cox proportional hazards regression models,
ncluding treatment arm, age (75 and 75 years), and age
y treatment interactions. Event-free survival was analyzed
y the Kaplan-Meier method comparing treatments by the
og-rank test. A p value 0.05 (2-tailed) was taken to
ndicate statistical significance.
esults
etween July 1, 2001, and August 31, 2006, 3,576 patients
dmitted to Christchurch Hospital with heart failure were
creened. In all, 998 met inclusion criteria; 823 patients
ere approached, and 448 consented to participate. Eighty-
our were subsequently excluded because NT-proBNP lev-
ls were 50 pmol/l. Three hundred sixty-four patients
ere randomized.
Treatment groups were well matched for relevant
aseline variables and test results (Table 2). Median ages
ere 75 to 76 years, and 75% of patients fell within
YHA functional classes II and III. A broad spectrum of
VEF was present (38  16%). tAt randomization, the proportion of patients receiving
ey drugs was similar across groups (furosemide in 94%,
8%, and 91%; ACEI/ARB in 84%, 84%, and 77%; BB in
5%, 70%, and 71%; and spironolactone in 12%, 12%, and
7% of NT-proBNP, CG, and UC groups, respectively).
nitial doses did not differ between groups but subsequent
oses of furosemide, ACEI, and BB were less in UC
atients than in either the NT-proBNP group or the CG
roup (p 0.001 for all) (Table 3). Accordingly, target drug
oses were met less often in the UC group compared with
he NT-proBNP and CG groups for both ACEI (28%,
8%, and 46%, respectively, at 12 months; p  0.001) and
B (15%, 21%, and 27%; p  0.001). Furosemide doses
ose significantly (p  0.001) above baseline in both the
T-proBNP and CG groups but not in the UC group
p  0.05 for UC vs. NT-proBNP group or CG group)
Table 3). Final achieved doses of furosemide were similar
n the NT-proBNP and CG groups, but the proportion of
isits in which furosemide doses were increased was signif-
cantly greater in the NT-proBNP group than in either the
G group or the UC group (17% vs. 14% and 9%; p 0.02
nd p  0.001, respectively). The ACEI doses did not alter
ignificantly over time in any group. The BB doses rose over
nitial follow-up similarly in NT-proBNP and CG groups
both p  0.001) but not in the UC group. Spironolactone
oses fell significantly within the NT-proBNP group of
atients (p  0.001 over follow-up) but were unchanged in
he CG and UC groups (Table 3).
Drugs were frequently decreased, predominantly reflect-
ng either symptomatic hypotension or azotemia (85% of
ccasions). Loop diuretic, ACEI, and BB doses were
educed at 9%, 7%, and 6% of reviews, respectively, with
ittle difference between treatment groups except in the case
f BBs, which were both increased and decreased signifi-
antly less often in the UC group than in either intensively
anaged group.
Plasma NT-proBNP levels fell similarly within 6 months
f randomization in both the NT-proBNP and CG groups
by 20% and 23%, respectively; p 0.001). Levels remained
bove 150 pmol/l in more than one-half of the patients in
he NT-proBNP and CG groups at 2 years (Table 3).
Minnesota scores improved significantly and similarly in
oth groups (both p  0.001), whereas 6-min walk distance
ended to improve in both groups (p  NS) (Table 3). The
roportions of patients in NYHA functional classes I, II, III,
nd IV did not differ significantly among NT-proBNP, CG,
nd UC at baseline (5.7%, 76.1%, 18.2%, and 0% vs. 11.1%,
2.2%, 16.7%, and 0% vs. 8.4%, 74.3%, 17.3%, and 0%,
espectively) nor between NT-proBNP and CG groups over
ollow-up (11.1%, 63.6%, 20.2%, and 5.1% vs. 11.0%, 59.0%,
5.0%, and 5.0%, respectively, at 12 months). The NT-
roBNP and CG patients attended for similar numbers of
cheduled and extra clinic visits (totaling 1,145 and 1,131 visits
or NT-proBNP and CG, respectively).
Mortality at 1 year was 18.9% in UC patients and 9.1% in
he NT-proBNP and CG groups (p 0.028 overall, p 0.03
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Hormone-Guided Treatment of Heart Failure December 29, 2009/January 5, 2010:53–60or both pairwise comparisons between UC and the other 2
roups). Univariate Kaplan-Meier analysis showed no overall
ifference in survival among groups at 2 and 3 years, but on
ox regression (allowing for time to event, age 75 or 75
ears, and time by age interactions), an overall treatment effect
panned the 3 years (p  0.033), driven primarily by a
ignificant difference between the NT-proBNP and UC
roups (p  0.011) (Fig. 1). We observed interactions (p 
.025) between treatment group and age with respect to
ortality (Fig. 2). At 1, 2, and 3 years among patients 75
ears of age, cumulative all-cause mortality was 1.7%, 7.3%,
nd 15.5%, respectively, in the NT-proBNP group; 7.3%,
0.0%, and 30.9%, respectively, in CG patients; and 20.3%,
3.4%, and 31.3%, respectively, in the UC group. Three-year
ortality was significantly lower for the younger NT-proBNP
atients than for their peers in either the CG or the UC group
p 0.048 and 0.021, respectively), whether analysis included
ll patients randomized (p  0.03) (Fig. 2) or was confined to
ubjects with follow-up of at least 3 years (n  215) from
Demographic and Clinical Characteristics of PatTable 2 Demographic and Clinical Characte
NT-proBNP–Guid
(n  121)
Age, yrs 76 (44–89)
Sex, % male 63
Blood pressure, mm Hg
Systolic 125 22
Diastolic 72 13
Heart rate, beats/min 71 13
Weight, kg 76 16
Diabetes mellitus 23
Hypertension 55
Coronary artery disease 70
History of myocardial infarction 42
Dilated cardiomyopathy 19
Stroke 23
Peripheral vascular disease 14
COPD 23
Plasma creatinine, mol/l 120 42
LVEF, % 40 15
NYHA functional class
I 12
II 68
III 18
IV 2
Heart failure admissions
0 69
1 31
Plasma NT-proBNP
pmol/l 238 (61–1,210
pg/ml 2,012 (516–10,2
Data are shown as median (interquartile range), %, or mean SD. Base
Mann-Whitney U statistic, chi-square test, and Fisher exact test, applie
COPD chronic obstructive pulmonary disease; LVEF left ventricu
NYHA  New York Heart Association.andomization (p  0.008). (For the coprimary end point of death and/or readmission
ith heart failure, Cox regression indicated reduced rates in
oth the NT-proBNP group (p  0.05) and the CG group
p  0.043) compared with UC patients at 1 year for those
75 years of age (Table 4). By 3 years, benefit was confined to
ounger NT-proBNP patients (p  0.044; cumulative event
ates of 39%, 51%, and 55% for younger NT-proBNP, CG,
nd UC groups, respectively). Accordingly, a comparison of
days alive and not in hospital with heart failure” for patients
ith potential follow-up of 1, 2, and 3 years favored patients
75 years in the NT-proBNP group: totals at 1, 2, and 3 years
veraged 360, 690, and 1,012 days, respectively, in the younger
T-proBNP patients; 352, 655, and 896 days, respectively, for
heir peers in the CG group; and 318, 584, and 806 days,
espectively, for patients receiving UC. The difference between
he NT-proBNP and UC groups in this regard was sustained
p 0.04, p 0.07, and p 0.04, respectively, at 1, 2, and 3
ears) whereas CG patients differed from patients in the UC
roup only for the first year (p  0.04) but not at 2 or 3 years
According to Subgroups of Patients According to Subgroup
Group
Clinically-Guided
(n  121)
Usual Care
(n  122)
76 (34–89) 75 (31–89)
67 62
123 24 125 22
70 12 73 14
71 13 69 13
75 16 76 15
20 22
42 62
72 73
47 44
23 27
20 21
11 14
20 16
122 49 119 44
39 15 37 15
7 7
66 67
25 25
2 1
67 71
32 29
236 (50–779) 238 (50–1,250)
1,996 (425–6,588) 2,012 (425–10,571)
riables did not differ between treatment groups as assessed by t tests,
ppropriate.
tion fraction; NT-proBNP N-terminal pro–B-type natriuretic peptide;ientsristic
ed
)
33)
line va
d as ap 0.11 and p 0.23, respectively). On average over 3 years
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December 29, 2009/January 5, 2010:53–60 Hormone-Guided Treatment of Heart Failuremong younger patients, the NT-proBNP group had 206
ore days (of a possible 1,076) alive and not in hospital with
eart failure than did the UC group (p  0.04).
Overall hospitalizations for heart failure (Table 4) did not
iffer among groups (cumulative event rates over 3 years of
6%, 40%, and 34% for NT-proBNP, CG, and UC groups,
espectively) although a nonsignificant reduction was ob-
erved among younger NT-proBNP patients (29% vs. 40%
nd 36%) (Table 4). No difference was seen for other
econdary outcomes, including death plus hospital admis-
ion for any cardiovascular event or for total admissions
data not shown).
The percentage of patients with heart failure scores 2.0
t clinic assessments fell in both the NT-proBNP and CG
roups (p  0.001) (Table 3). The fall was more pro-
ounced in NT-proBNP patients (over all visits, 6.6% vs.
2.1%, respectively; p  0.03).
No significant benefit was observed from NT-proBNP or
G over UC among patients 75 years of age. Patients 75
ears of age received lower drug doses (88%, 79%, and 50% of
edications and Serial MeasuresTable 3 Medications and Serial Measures
Drug Treatment Group 0
Furosemide, mg/day NT-proBNP* 128 23
CG* 149 23
UC† 124 22
ACEI, mg/day NT-proBNP 12.7 6
CG 13.3 6
UC 10.3 6
Beta-blocker, mg/day NT-proBNP‡ 76 11
CG‡ 80 11
UC† 73 10
Spironolactone, mg/day NT-proBNP§ 20 6
CG 21 6
UC 20 2
6-min walk distance, m NT-proBNP 337 103
CG 337 98
UC 345 95
Quality of life score NT-proBNP 36.5 22.7
CG 36.6 23.1
UC 36.5 24.0
NT-proBNP 150 pmol/l NT-proBNP§ 66
CG§ 79
Heart failure score 2.0 NT-proBNP§¶ 14
CG§ 14
eGFR, ml/min NT-proBNP§ 57 18
CG§ 61 20
BP systolic, mm Hg NT-proBNP§ 125 14
CG§ 123 13
BP diastolic, mm Hg NT-proBNP§ 72 12
CG§ 70 12
ata are shown as mean  SD or %. Mean doses are for patients receiving drug. Angiotensin-conv
n metoprolol equivalents. *Dose increased over follow-up, p 0.001. †No significant change in do
atriuretic peptide (NT-proBNP) group and clinically-guided (CG) group, p  0.05. ‡BB doses rise in
 0.001. ¶NT-proBNP group less than CG group over 24 months, p  0.04.
BP  blood pressure; eGFR  estimated glomerular filtration rate; UC  usual care.oses at 12 months for patients 75 years of age for furo- remide, ACEI, and BB, respectively; p  0.001 for all) and
et target doses less often (in 30% vs. 50% and 12% vs. 27%
or ACEIs and BBs, respectively, at 12 months; p 0.001 for
oth), had higher baseline (296  179 pmol/l vs. 265  233
mol/l; p 0.001) and subsequent plasma NT-proBNP levels
hat remained above 150 pmol/l more often (66% to 84% vs.
8% to 57% of serial 3-monthly measurements; p  0.001),
nd had poorer renal function (baseline estimated glomerular
ltration rate 52  17 ml/min/1.73 m2 vs. 60  21 ml/min/
.73 m2; p  0.001) than did patients 75 years of age.
otably, LVEF was higher in older patients (42.1 12.7% vs.
4.7  12.6%; p  0.001). LVEF was preserved (i.e., 40%)
n 29% and 53% of patients age 75 years and 75 years,
espectively. All age-associated differences were similar across
reatment groups.
iscussion
ailored treatment is accepted for many disorders, including
iabetes mellitus and hypertension. For CHF, the issue
Time (Months)
3 6 12 24
138 20 140 22 182 22 200 27
144 21 134 21 166 23 197 28
121 21 119 21 123 22 140 25
13.0 6 13.3 6 13.1 6 12.4 7
14.7 6 14.6 6 14.2 6 14.0 7
11.3 6 11.0 6 11.0 6 10.8 6
83 9 95 9 95 10 94 11
91 9 95 9 99 10 99 12
74 9 75 9 73 10 72 10
22 4 22 4 20 5 16 7
22 5 24 5 23 5 20 6
20 2 21 2 21 2 21 3
356 106 364 109
369 93 369 97
28.9 24.5 28.8 21.6
27.5 20.0 26.5 22.0
67 58 57 51
71 57 63 68
5 3 9 4
9 13 10 4
56 18 56 18 55 17 52 16
59 20 60 20 59 19 56 19
124 13 125 15 123 12 122 12
122 12 122 13 119 15 119 13
71 12 70 11 70 11 69 10
70 12 70 12 69 12 68 12
nzyme inhibitor (ACEI) doses are given in enalapril equivalents. Beta-blocker (BB) doses are given
either average dose or increment in dose over follow-up is less than in the N-terminal pro–B-type
months, p  0.001. §Significant falls over 24 months, p  0.001. Quality of life score improves,erting e
se, and
first 6emains unsettled. Whereas a single-center study (11) and a
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Hormone-Guided Treatment of Heart Failure December 29, 2009/January 5, 2010:53–60ulticenter trial (12) documented outcome benefits from
harmacotherapy guided by BNP peptides, they have been
riticized on a number of grounds, guidelines have yet to
ndorse the concept, and the view exists that clinicians do
ot need “such a crutch” (19). The present trial was
esigned to overcome current uncertainties by including a
arger number of patients, less selected than in the 2
eported studies (11,12), in other words, typical of patients
dmitted with CHF in Western countries. Follow-up was
onger than in earlier studies, and we compared the efficacy
f NT-proBNP–guided treatment not only with intensive
linical management but also with UC.
Survival at 1 year was superior in both groups followed up
ntensively compared with UC. These observations support
revious reports regarding the effectiveness of systematic
ultidisciplinary care employing a variety of monitoring
trategies for CHF in which reduced mortality has been the
ost consistently improved end point (20–23). Survival
enefit at 1 year was driven by patients 75 years of age,
nd for those 75 years of age, the 1-year mortality did not
iffer among groups (Fig. 2). The same applies to 2- and
-year data except that, at these time points, survival among
75-year-old patients was significantly greater in the NT-
roBNP group versus both of the other 2 groups.
The NT-proBNP patients (all ages) were significantly
ess likely to have heart failure scores 2 during 2 years of
ollow-up than were CG patients. For the coprimary end
oint of death and/or readmission to hospital with CHF at
year, the 2 intensively managed groups had a significantly
Figure 1 3-Year Survival of Patients With
Chronic Symptomatic Heart Failure
Three-year survival of patients with chronic symptomatic heart failure receiving
hormone-guided treatment (red line), clinically-guided treatment (green line), or
usual care (blue line). All patients irrespective of age are included. An overall
treatment effect was confirmed by Cox hazards analysis at 1, 2, and 3 years
(p  0.05 for all analyses), driven mainly by a significant difference between
hormone-guided and usual care groups (p  0.011 over 3 years). The vertical
dashed line indicates cessation of management strategy and return to stan-
dard clinical practice for all surviving participants at 2 years.etter outcome than did UC patients among those 75ears of age, but not among older patients. Again, by 3
ears, this outcome favored NT-proBNP–guided patients
ver those in the other 2 groups (again, only among patients
75 years of age). Hence, our second hypothesis, that
harmacotherapy titrated according to plasma levels of
T-proBNP would result in clinical outcomes superior to
anagement guided by a heart failure score based on
ntensive standardized clinical assessment, can be answered
n the affirmative—but with age- and time-related caveats.
e cannot fully explain the late-emerging advantage of
ormone-guided treatment over intensive clinical manage-
Figure 2 Survival of Patients <75 and >75 Years
of Age With Chronic Symptomatic Heart Failure
Survival among patients (A) 75 years of age and (B) 75 years of age with
chronic symptomatic heart failure receiving hormone-guided treatment (red
lines), clinically-guided treatment (green lines), or usual care (blue lines). Ver-
tical dashed lines indicate cessation of treatment strategy and return to stan-
dard clinical practice for all surviving participants at 2 years. At 1 year, in the
75-year-old group, both hormone-guided and clinically managed groups had
lower mortality than did the usual care group (p  0.05 for both comparisons).
At 3 years, the younger hormone-guided group had lower mortality than both
other groups (p  0.05 for both comparisons), and mortality in the clinically
managed group no longer differed from that in the usual care group.
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December 29, 2009/January 5, 2010:53–60 Hormone-Guided Treatment of Heart Failureent. However, increments in loop diuretics were instituted
ignificantly more frequently and may have been more
ptimally matched to individual patient needs in the NT-
roBNP group even in the absence of differences in final
ean doses between the NT-proBNP and UC groups. The
ata suggest sustained benefit, and no net harm, accrues
rom increased loop diuretic doses when added to maximally
olerated doses of ACEI and BB for patients with persistent
levation of plasma NT-proBNP but without bedside signs
r symptoms of cardiac decompensation. The CG patients
eceived more intensive follow-up and frequent adjustment
f therapy than would be expected in routine clinical
ractice, but at 3 years this conferred no advantage, in
ontrast to UC. That may reflect cessation of this manage-
ent strategy at 2 years from randomization with loss of
ffect within the following 12 months (Fig. 2). The
ormone-guided approach may have allowed establishment
f more effective individualized therapy within the 2-year
indow with longer-lasting beneficial effects.
At the time of writing, the TIME-CHF (Trial of
ntensified vs. Standard Medical Therapy in Elderly Pa-
ients With Congestive Heart Failure) trial of NT-
roBNP–guided versus symptom-guided therapy was pub-
ished (24,25). The trial was conducted with 499 patients
60 years of age randomly allocated to the 2 treatment
trategies and followed up for 18 months. The results are in
triking parallel to the current report, with improvement in
utcomes among patients 60 to 75 years of age but not
linical OutcomesTable 4 Clinical Outcomes
Treatment Group
Age
Group
(yrs)
Year
1 2 3
Death  heart failure admission
NT-proBNP All 36 (30) 52 (43) 64 (53)
75* 14 (24) 20 (34) 23 (39)
75 22 (35) 32 (51) 41 (65)
CG All 36 (30) 57 (47) 66 (55)
75 15 (27) 25 (45) 28 (51)
75 21 (32) 32 (48) 38 (58)
UC All 42 (34) 57 (47) 66 (54)
75 25 (39) 31 (48) 35 (55)
75 17 (29) 26 (45) 31 (53)
Heart failure admission
NT-proBNP All 29 (24) 38 (31) 44 (36)
75 13 (22) 16 (28) 17 (29)
75 16 (25) 22 (35) 27 (43)
CG All 30 (25) 44 (36) 49 (40)
75 14 (25) 21 (38) 22 (40)
75 16 (24) 23 (35) 27 (41)
UC All 26 (21) 37 (30) 41 (34)
75 18 (28) 22 (34) 23 (36)
75 8 (14) 15 (26) 18 (31)
alues are n (%). *Significantly less than UC at 3 years (p  0.044).
Abbreviations as in Table 3.mong those 75 years of age or older. fIt is evident from our results and the foregoing discussion
hat patient age has a modulating effect on the clinical
fficacy of NT-proBNP–guided therapy. Benefits were
onfined to patients 75 years of age, broadly consistent
ith the 2 previous studies in which the average age of
atients was considerably younger, age 70 years (11) and
66 years (12), than in the present trial, age 76 years.
atients age 75 years of age were less able to tolerate full
rial-based doses of drugs, and had reduced renal function.
n addition, older patients included a higher proportion
ith preserved LVEF, a group in which the efficacy of
stablished heart failure therapy is uncertain (26,27). These
actors presumably underlie, or at least contribute to, the
ack of benefit in this subgroup.
In the subgroup for which mortality benefit was most
pparent (i.e., patients75 years of age receiving hormone-
uided treatment), achieved doses of loop diuretics were
igher than in UC patients and dose adjustments were more
requent than in both the UC and CG groups. Furosemide
as no fixed, trial-based, standard or target dose and has a
road therapeutic range between 20 mg and 3 g daily.
learly, this is where most flexibility resides for altering
eart failure therapy once a full attempt has been made to
chieve trial-based doses of ACEIs/ARBs and BBs.
ounger versus older patients with adequate renal reserve
nd preserved autonomic function are likely to be better able
o compensate for any adverse hemodynamic effects of
ncreasing doses of loop diuretic.
Patients in the NT-proBNP–guided group and the CG
roup had a similar total number of visits to the outpatient
linic. This finding suggests that the benefit of hormone
uidance does not reflect differences in frequency of patient
ontact with attendant increased opportunity for promotion
f drug compliance, better education, and/or promotion of
onpharmacological measures.
We utilized a single level of plasma NT-proBNP (150
mol/l) in our NT-proBNP group as a target for pharma-
otherapy independent of patient age. Because levels of the
-type peptides increase with age, it might in retrospect
ave been logical to have used age-adjusted peptide levels or
ven individualized target peptide levels for guiding
reatment.
onclusions
e have shown that, compared with UC in the community,
ntensive management with or without guidance from serial
easurements of plasma NT-proBNP improves mortality
t 1 year among patients with CHF. Hormone-guided
reatment was associated with a lower mortality rate (and
lso reduced mortality plus hospitalization rate) at 3 years
ompared with either intensive clinical management or UC
or patients 75 years of age.
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